SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated Phase 2 lung-cancer data triggered a sharp selloff: lifileucels overall response rate was 24.6%, while a small biomarker-selected subgroup showed a higher rate of 59.1%. Traders are divided between viewing the subgroup results as a promising path for precision treatment and worrying that the narrower population, need for further validation, and potentially longer route to approval weaken the opportunity.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets earnings miss and sharp selloff are drawing attention, with slower Search and advertising growth, heavy AI infrastructure spending, and negative free cash flow fueling concerns about monetization and returns. Many traders call the drop an overreaction and are buying the dip on Cloud and AI optimism, while others see lasting pressure from AI competition and weaker Search economics.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows quarterly results and softer outlook for near-term contracted revenue growth triggered a sharp selloff, despite revenue growth and stronger AI targets. Traders are split between calling the move an overreaction and arguing that slowing contract growth, high expectations, and uncertainty over AIs impact on software justify the repricing.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss has triggered a sharp selloff, with traders focused on slower Search and advertising growth and heavy AI infrastructure spending weighing on cash flow. Some see the decline as an overreaction given strong Cloud growth and are buying the dip, while others question whether AI investments can generate returns and whether AI is eroding Google Searchs business.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts quarterly earnings beat and accelerating Azure growth, with stronger cloud guidance, drew attention, but shares faded after the initial rally. Traders debated whether AI infrastructure spending, weaker free cash flow and a new bond offering weighed on the stock, while others argued strong cloud demand supports the investment; some also blamed broader tech weakness following Alphabets results.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians quarterly earnings beat expectations and its raised full-year outlook are driving a sharp rally. Many traders are celebrating the results and speculating about short covering, while others are taking profits and flagging debt, fuel costs, and lingering yield concerns.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs quarterly results and outlook are driving the rally, with traders highlighting improved profitability, margins and cash generation alongside stronger EBITDA guidance. Bulls see signs of a turnaround and speculate about a short squeeze, while skeptics point to declining revenue and ongoing BetterHelp weakness.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as traders connect its move to strength in Hyperliquids HYPE token, with some expecting the digital-asset treasury stock to catch up and speculating about short covering. Others argue that potential share dilution and PURRs lagging performance versus HYPE could limit gains.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 results are driving attention, with record vehicle sales and revenue growth lifting shares despite an earnings-per-share miss. Traders are divided between those welcoming the sales momentum and outlook and those focused on margin compression, debt, and auto-credit risks.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention for holding up relatively well as technology and semiconductor stocks sell off, renewing discussion of a rotation into small caps. Traders debate whether the strength signals a lasting recovery or a temporary bounce, with elevated oil prices, yields, and uncertainty around Fed policy weighing on sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.read more...

FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints

Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.read more...

Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’

Equity

The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism


RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?

Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.read more...

Rezolute (RZLT) to Release Quarterly Earnings on Tuesday

Rezolute (NASDAQ:RZLT) will be releasing its Q3 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...

Rezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in March

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 13,353,457 shares, a decline of 21.2...

What is HC Wainwright's Estimate for Rezolute Q1 Earnings?

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - HC Wainwright cut their Q1 2027 EPS estimates for Rezolute in a research report issued on Monday, March 30th. HC Wainwright analyst D. Tsao now...

Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update

RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.

Rezolute (NASDAQ:RZLT) Stock Rating Upgraded by Wedbush

Wedbush upgraded Rezolute from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $2.00 to $5.00 in a report on Wednesday...

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Rezolute Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Rezolute’s Phase 3 sunRIZE study missed its primary and key secondary endpoints.</li><li>FDA reviewed additional analysis, including glucose-monitoring data, before suggesting a pre-BLA meeting.</li><li>The study’s open-label extension is still ongoing.</li></ul>Rezolute (RZLT) was on investors’ radar in pre-market trading on Monday after the biotech firm received a positive regulatory update on its therapy for a rare genetic disorder of the pancreas, potentially taking it closer to official filing.<a class="mention" data-mention="$RZLT" data-symbol-id="RZLT" href="https://stocktwits.com/symbol/RZLT" target="_blank">RZLT shares</a> jumped more than 10% after the update but pared most of the gains as of this writing.<h2 class="st-heading-2">FDA Recommends Pre-BLA Meeting</h2>The U.S. Food and Drug Administration (FDA) recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism. This is notable because Rezolute’s Phase 3 sunRIZE study failed to meet its primary and key secondary endpoints.However, after reviewing additional analysis, including glucose-monitoring data, submitted by the company, the FDA recommended that Rezolute request a meeting that acts as a precursor to submitting a potential Biologics License Application (BLA) for drug commercialization. A pre-BLA meeting is a discussion on the planned filing and to identify any issues before submission.The study’s open-label extension is still ongoing, with many patients continuing Ersodetug. Rezolute said that continued blood sugar control and reduced need for other standard treatments may suggest the drug provides lasting clinical benefit with longer-term use.<h2 class="st-heading-2">Rezolute Paused RZ402 Program To Focus On Ersodetug</h2>Ersodetug is also being studied in the Phase 3 upLIFT trial for tumor hyperinsulinism, with topline results expected this quarter. Interim data released earlier this year showed six of the first eight patients met the study’s primary goal.Rezolute is also evaluating Ersodetug for hypoglycemia following gastrointestinal surgery. Its earlier RZ402 program for diabetic macular edema (DME) was paused after Phase 2 trials as the company shifted resources toward Ersodetug.<h2 class="st-heading-2">Retail Calls FDA Decision A Big Win</h2>Retail sentiment for RZLT on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.<img src="https://news.stocktwits-cdn.com/rzlt_c0e66e9aa1.png" alt="rzlt.png">One user said the stock is set for a ‘huge rerating’<stembedurl>https://stocktwits.com/Monty3030/message/665742216</stembedurl>Another user said it is a “big win, but the market doesn’t seem to agree.”<stembedurl>https://stocktwits.com/oaksapollo/message/665744852</stembedurl>The stock has surged more than 84% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rgnx-stock-up-today-mizuho-regenxbio/cZDpvflRBSv">Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism

SPDR S&P Biotech ETF

$AMZN

$INTC

$RDDT

$SNDK

Which earnings release after the close will you be watching closest: $AMZN, $INTC, $RDDT, or $SNDK? 

Drop a comment for other tickers like $COIN, $SBUX, and $TWLO.

Current Price	$4.19
Prev Close	$4.22
Open	$4.29
Dividend Yield	0.00%
50-Day Moving Average	$4.28
Beta	0.91
Avg. Volume	1.54M
PE Ratio	-5.65

52-Week High	$11.46
52-Week Low	$1.07
Market Capitalization	$408.2M
EPS (Annual)	-$0.7467
Price to Book	4.04
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

RZLT Fundamentals